Month: April 2025

At #EAU25, Professor Xiongjun Ye (叶雄俊) from Peking Union Medical College Hospital shared his team’s latest findings on MRI accuracy in renal tumor diagnosis, tumor heterogeneity in RCC, and strategies for managing postoperative recurrence. His group’s EAU-selected research explores how imaging limitations and intratumoral heterogeneity affect treatment outcomes—offering new perspectives for optimizing RCC care.

At #EAU25, we spoke with Prof. Haibin Chen and Prof. Ruiyi Zhang from Renji Hospital, Shanghai Jiao Tong University, who shared updates on their team's research in muscle-invasive bladder cancer (MIBC). They discussed a new study exploring ADC therapy for HER2+ MIBC, as well as progress in bladder-sparing treatment, ctDNA-based monitoring, and AI-driven molecular profiling for personalized treatment decisions.

At hashtag#EAU25, Prof. Shousheng Chen (陈守臻) from Qilu Hospital of Shandong University shared key findings from his study on a "biopsy-free" diagnostic approach for prostate cancer using PSMA PET/CT, mpMRI, and serum biomarkers. He discussed how this strategy compares with traditional PSA and DRE, its potential in early diagnosis, and how it could guide follow-up and monitoring.

At hashtag#EAU25 in Madrid, we had the opportunity to interview Professor Liangyou Gu from the General Hospital of the Chinese PLA, who shared his clinical perspective on emerging treatment strategies for muscle-invasive bladder cancer (MIBC). With ongoing breakthroughs in MIBC research, bladder-sparing approaches are gaining traction alongside radical cystectomy. Prof. Gu offered his insights on how clinicians can evaluate the best option for each patient, especially in the context of neoadjuvant therapy.